Equillium partner Biocon reported data from a clinical trial showing that itolizumab significantly decreased mortality in hospitalized COVID-19 patients.
Atox Bio had positive results in the company’s Phase III ACCUTE trial for reltecimod for early treatment of severe Necrotizing Soft Tissue Infection (NSTI), a so-called flesh-eating disease.
BioNTech and Pfizer’s Covid-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported, citing the German biotech firm’s chief executive officer.
Gilead Sciences reported additional data from the company’s Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
The U.S. Food and Drug Administration will review GlaxoSmithKline’s experimental treatment for multiple myeloma, a common form of blood cancer, for a reported side effect which affects the eyes of patients.
A clinical trial of Fujifilm Holdings’ Avigan drug yielded inconclusive results as a treatment of COVID-19, Japanese researchers said on Friday.
Harbour BioMed closed a $102 million Series C funding round that will be used to advance the company’s oncology and immunology portfolio.
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
Evive Biotech announced that the company’s Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients met the primary and secondary endpoints.
Gilead Sciences started an early-stage study of the company’s antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
